Key takeaways
Levetiracetam (Keppra) and lacosamide (Vimpat) are both antiepileptic medications used to treat seizures, but they have some key differences. Levetiracetam is available in both immediate-release and extended-release forms, while lacosamide is available in immediate-release and extended-release capsules. Levetiracetam is not a controlled substance, whereas lacosamide is a Schedule V controlled substance, meaning it has a potential for misuse and dependence. Levetiracetam can be used for partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures, while lacosamide is used for partial-onset seizures and as an add-on for primary generalized tonic-clonic seizures. Common side effects of levetiracetam include sleepiness, weakness, and headaches, while lacosamide often causes dizziness, headaches, and nausea. Additionally, levetiracetam is known to cause mood changes and behavioral issues, especially in children, whereas lacosamide can cause abnormal heartbeats and fainting. Both medications require careful monitoring and should not be stopped abruptly to avoid withdrawal seizures.
